EYPT Q3 2021 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-42.3% YoY

Gross Profit

$7M79.9% margin

Operating Income

-$15M-169.0% margin

Net Income

-$17M-184.3% margin

EPS (Diluted)

$-0.58

QoQ Revenue Growth

+0.5%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$168M

Total Liabilities

$76M

Stockholders' Equity

$93M

Cash & Equivalents

$120M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$16M	-42.3%
Gross Profit	$7M	$14M	-47.6%
Operating Income	-$15M	-$2M	-682.5%
Net Income	-$17M	-$4M	-339.2%

Revenue Segments

Product

$9M50%

D E X Y C U Product

$5M27%

Y U T I Q Product

$4M23%